Published in Mol Pharmacol on October 22, 2010
Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose? Future Med Chem (2012) 1.10
Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One (2012) 1.08
Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One (2013) 1.06
Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology (2011) 1.06
Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse. PLoS Comput Biol (2012) 1.04
Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci U S A (2015) 1.01
Preparation and in vivo characterization of a cocaine hydrolase engineered from human butyrylcholinesterase for metabolizing cocaine. Biochem J (2013) 0.96
Pharmacokinetic strategies for treatment of drug overdose and addiction. Future Med Chem (2012) 0.95
Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets (2011) 0.95
Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem (2012) 0.90
A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nat Commun (2014) 0.90
Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem J (2014) 0.89
Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend (2011) 0.87
Catalytic activities of a cocaine hydrolase engineered from human butyrylcholinesterase against (+)- and (-)-cocaine. Chem Biol Interact (2012) 0.86
Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines (2013) 0.86
Substrate selectivity of high-activity mutants of human butyrylcholinesterase. Org Biomol Chem (2013) 0.86
Kinetic characterization of human butyrylcholinesterase mutants for the hydrolysis of cocaethylene. Biochem J (2014) 0.83
Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys. J Pharmacol Exp Ther (2012) 0.83
His-tag truncated butyrylcholinesterase as a useful construct for in vitro characterization of wild-type and variant butyrylcholinesterases. Protein Expr Purif (2011) 0.82
Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity. Future Med Chem (2012) 0.81
Cocaine esterase-cocaine binding process and the free energy profiles by molecular dynamics and potential of mean force simulations. J Phys Chem B (2012) 0.81
Evaluation of the hydrolytic activity of a long-acting mutant bacterial cocaine in the presence of commonly co-administered drugs. Drug Alcohol Depend (2011) 0.80
Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity. Chem Biol Interact (2012) 0.80
Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction. Future Med Chem (2012) 0.79
Psychostimulant-related deaths among former inmates. J Addict Med (2012) 0.79
Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem J (2015) 0.78
Reaction pathways and free energy profiles for cholinesterase-catalyzed hydrolysis of 6-monoacetylmorphine. Org Biomol Chem (2014) 0.78
Metabolic Enzymes of Cocaine Metabolite Benzoylecgonine. ACS Chem Biol (2016) 0.77
Effects of a cocaine hydrolase engineered from human butyrylcholinesterase on metabolic profile of cocaine in rats. Chem Biol Interact (2016) 0.77
Potential anti-obesity effects of a long-acting cocaine hydrolase. Chem Biol Interact (2016) 0.76
Protein engineering: a new frontier for biological therapeutics. Curr Drug Metab (2014) 0.76
Reaction Pathway for Cocaine Hydrolase-Catalyzed Hydrolysis of (+)-Cocaine. Theor Chem Acc (2015) 0.75
Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches. Bioorg Med Chem (2013) 0.75
Metabolism of β-valine via a CoA-dependent ammonia lyase pathway. Appl Microbiol Biotechnol (2015) 0.75
Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. BMC Biotechnol (2016) 0.75
Harnessing Nature's Diversity: Discovering organophosphate bioscavenger characteristics among low molecular weight proteins. Sci Rep (2016) 0.75
Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users. Am J Drug Alcohol Abuse (2014) 0.75
Unexpected Reaction Pathway for butyrylcholinesterase-catalyzed inactivation of "hunger hormone" ghrelin. Sci Rep (2016) 0.75
Free energy profiles of cocaine esterase-cocaine binding process by molecular dynamics and potential of mean force simulations. Chem Biol Interact (2016) 0.75
Antibody-catalyzed degradation of cocaine. Science (1993) 3.28
Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A (2005) 2.63
Neurobiology of butyrylcholinesterase. Nat Rev Neurosci (2003) 2.41
Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33
Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend (1997) 2.29
Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol (2002) 2.21
A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology (2008) 2.07
Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc (2003) 1.97
Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther (2002) 1.91
Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther (1996) 1.81
Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A (2004) 1.75
Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B (2005) 1.73
New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol (2007) 1.70
First-principle studies of intermolecular and intramolecular catalysis of protonated cocaine. J Comput Chem (2005) 1.68
Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol (2006) 1.66
Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc (2007) 1.63
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol (2008) 1.60
Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther (2006) 1.55
Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl (2006) 1.55
Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine. Biophys J (2005) 1.50
Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc (2005) 1.48
Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol (1991) 1.48
Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc (2008) 1.45
Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J Phys Chem B (2005) 1.44
Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins (2006) 1.43
Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact (2010) 1.39
An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact (2008) 1.34
Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta (1999) 1.28
Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol (1997) 1.27
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J (2009) 1.25
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther (2009) 1.19
A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse. Mol Pharmacol (2010) 1.12
Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel (2010) 1.10
Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry (2010) 1.09
Pharmacokinetic approaches to treatment of drug addiction. Expert Rev Clin Pharmacol (2008) 1.03
The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study. Prog Neurobiol (2000) 0.88
Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med (2013) 2.85
A strong ferroelectric ferromagnet created by means of spin-lattice coupling. Nature (2010) 2.63
Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A (2005) 2.63
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem (2004) 2.55
Retracted Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med (2010) 2.43
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A (2004) 2.42
Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat (2002) 2.36
Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc (2003) 1.97
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol (2003) 1.91
EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut (2011) 1.87
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol (2007) 1.84
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med (2008) 1.77
A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol (2009) 1.76
Molecular dynamics simulation of cocaine binding with human butyrylcholinesterase and its mutants. J Phys Chem B (2005) 1.73
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology (2004) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2010) 1.69
Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol (2006) 1.66
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65
Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc (2007) 1.63
Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum (2010) 1.62
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol (2008) 1.60
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis (2004) 1.57
Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci (2011) 1.57
Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther (2006) 1.55
Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl (2006) 1.55
The economics of drug abuse: a quantitative assessment of drug demand. Mol Interv (2005) 1.54
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci (2004) 1.53
Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron (2012) 1.51
Acid-sensing ion channels contribute to the effect of acidosis on the function of dendritic cells. J Immunol (2011) 1.50
Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc (2008) 1.45
Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology (2002) 1.45
Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J Phys Chem B (2005) 1.44
PotD protein stimulates biofilm formation by Escherichia coli. Biotechnol Lett (2013) 1.44
Modeling evolution of hydrogen bonding and stabilization of transition states in the process of cocaine hydrolysis catalyzed by human butyrylcholinesterase. Proteins (2006) 1.43
The biology behind fascial defects and the use of implants in pelvic organ prolapse repair. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.42
Comparison of host response to polypropylene and non-cross-linked porcine small intestine serosal-derived collagen implants in a rat model. BJOG (2005) 1.41
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact (2010) 1.39
Glycoprotein Ia C807T: Polymorphisms and Their Association with Platelet Function in Patients with the Acute Coronary Syndrome. Cardiology (2015) 1.39
Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity (2011) 1.38
Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice. Mol Med (2012) 1.37
First-principles calculation of pKa for cocaine, nicotine, neurotransmitters, and anilines in aqueous solution. J Phys Chem B (2007) 1.34
Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol (2011) 1.34
Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther (2008) 1.31
Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther (2007) 1.31
How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J (2007) 1.27
Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther (2004) 1.25
Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J (2009) 1.25
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol (2005) 1.24
LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY. J Med Chem Biol Radiol Def (2005) 1.24
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
A catenated strut in a catenated metal-organic framework. Angew Chem Int Ed Engl (2010) 1.22
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol (2010) 1.21
Carbon monoxide enhances salt tolerance by nitric oxide-mediated maintenance of ion homeostasis and up-regulation of antioxidant defence in wheat seedling roots. Plant Cell Environ (2008) 1.20
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther (2009) 1.19
Theoretical studies of the transition-state structures and free energy barriers for base-catalyzed hydrolysis of amides. J Phys Chem A (2006) 1.19
Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) (2002) 1.18
Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology (2009) 1.18
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology (2003) 1.18
Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharmacology (Berl) (2011) 1.18
Patterns of nicotinic receptor antagonism: nicotine discrimination studies. J Pharmacol Exp Ther (2011) 1.18
Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome. J Cell Sci (2009) 1.17
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
A mechanical actuator driven electrochemically by artificial molecular muscles. ACS Nano (2009) 1.16
Integrated materials design of organic semiconductors for field-effect transistors. J Am Chem Soc (2013) 1.16
PCM1 recruits Plk1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry. J Cell Sci (2013) 1.15
Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther (2002) 1.15
Fundamental reaction mechanism and free energy profile for (-)-cocaine hydrolysis catalyzed by cocaine esterase. J Am Chem Soc (2009) 1.15
Reaction pathways and free energy barriers for alkaline hydrolysis of insecticide 2-trimethylammonioethyl methylphosphonofluoridate and related organophosphorus compounds: electrostatic and steric effects. J Org Chem (2004) 1.15
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res (2007) 1.14
Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol (2013) 1.14